Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

Triple combination of atezolizumab, vemurafenib, and cobimetinib had proven its efficacy and tolerability in real settings. No impact of potential predictive biomarkers was seen (NCT05402059).

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2024-10-14
DOI
https://doi.org/10.3389/fonc.2024.1395378
Citations
5
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
1.17
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

Igor Utyashev, Ivan I. Butkov, Lev Demidov, Natalia Beliaeva et al.
5 citations
Frontiers in Oncology
Melanoma and MAPK Pathways
1.17
article

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

Igor Utyashev, Ivan I. Butkov, Lev Demidov, Natalia Beliaeva, К. V. Menshikov, Н. А. Савелов, Yu.M. Kolontareva, K. G. Babina, Yu. V. Vakhabova, Kristina V. Orlova, Е. В. Карабина, V. D. Sychev, Игорь Вячеславович Самойленко, Maksim V. Zinkevich, Natalia V. Zhukova, M. Е. Ivannikov, Vera V. Chernova, Alexander Yurchenkov, Mikhail Volkonsky, E. V. Kogay, Tatyana L. Moskovkina, Kseniya A. Moshkova, Olga V. Plishkina, Oxana S. Cheplukhova
article en
5 citations

Abstract

Triple combination of atezolizumab, vemurafenib, and cobimetinib had proven its efficacy and tolerability in real settings. No impact of potential predictive biomarkers was seen (NCT05402059).

Frontiers in OncologyVol. 14
Nizhny Novgorod Regional Clinical Oncology Center (RU), City Clinical Oncology Center (RU), Orenburg Regional Clinical Oncology Center (RU), Kirov State Medical Academy (RU), Guz "Tul'skiy Oblastnoy Onkologicheskiy Dispanser (RU), Murmansk Regional Oncology Center (RU), State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU), Volgograd Regional Clinical Oncology Center (RU), Tyumen State Medical University (RU), Moscow City Oncology Hospital №62 (RU)
Openalex Percentile: Top 21%
Melanoma and MAPK Pathways
1.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.